Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (Immunomodulatory Treatment of Early-onset MS) study group

被引：0
|
作者：
Ghezzi, A
Amato, MP
Gallo, P
Marrosu, MG
Martinelli, V
Milani, N
Milanese, C
Moiola, L
Patti, F
Pozzilli, C
Trojano, M
Zaffaroni, M
Pilato, V
Comi, G
机构：
来源：
MULTIPLE SCLEROSIS | 2004年 / 10卷 / 7032期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S234 / S234
页数：1
相关论文
共 50 条
  • [21] Factors associated with early disease-modifying drug (DMD) treatment initiation in newly diagnosed patients with multiple sclerosis (MS)
    Phillips, A. L.
    Edwards, N. C.
    Frean, M.
    Locklear, J. C.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 601 - 601
  • [22] Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)
    Wiendl, Heinz
    Gold, Ralf
    Berger, Thomas
    Derfuss, Tobias
    Linker, Ralf
    Maeurer, Mathias
    Stangel, Martin
    Aktas, Orhan
    Baum, Karl
    Berghoff, Martin
    Bittner, Stefan
    Chan, Andrew
    Czaplinski, Adam
    Deisenhammer, Florian
    Di Pauli, Franziska
    Du Pasquier, Renaud
    Enzinger, Christian
    Fertl, Elisabeth
    Gass, Achim
    Gehring, Klaus
    Gobbi, Claudio
    Goebels, Norbert
    Guger, Michael
    Haghikia, Aiden
    Hartung, Hans-Peter
    Heidenreich, Fedor
    Hoffmann, Olaf
    Hunter, Zoe R.
    Kallmann, Boris
    Kleinschnitz, Christoph
    Klotz, Luisa
    Leussink, Verena
    Leutmezer, Fritz
    Limmroth, Volker
    Luenemann, Jan D.
    Lutterotti, Andreas
    Meuth, Sven G.
    Meyding-Lamade, Uta
    Platten, Michael
    Rieckmann, Peter
    Schmidt, Stephan
    Tumani, Hayrettin
    Weber, Martin S.
    Weber, Frank
    Zettl, Uwe K.
    Ziemssen, Tjalf
    Zipp, Frauke
    NERVENARZT, 2021, 92 (08): : 773 - 801
  • [23] Disease-modifying and neuroprotective efficacy of exercise therapy early In the disease course of multiple sclerosis - The Early Multiple Sclerosis Exercise Study (EMSES)
    Riemenschneider, M.
    Hvid, L. G.
    Ringgaard, S.
    Nygaard, M. K. E.
    Eskildsen, S. F.
    Gaemelke, T.
    Magyari, M.
    Jensen, H. B.
    Nielsen, H. H.
    Kant, M.
    Falah, M.
    Petersen, T.
    Stenager, E.
    Dalgas, U.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 87 - 87
  • [24] Economic analysis of treatment of multiple sclerosis with Tysabri alternative to standard disease-modifying drugs in Norway
    Svendsen, B.
    Aarseth, J. H.
    Nyland, H.
    Myhr, K. -M.
    MULTIPLE SCLEROSIS, 2007, 13 : S261 - S261
  • [25] Treatment with disease-modifying drugs does not alter disability in relapsing-remitting multiple sclerosis
    Rolak, Loren A.
    Bejaoui, Khemissa
    Matti, Charmaine
    Foss, Dawn
    MULTIPLE SCLEROSIS, 2008, 14 : S176 - S176
  • [26] Disease-modifying therapy of paediatric onset multiple sclerosis. A nationwide Danish cohort study
    Erdal, J. L.
    Kopp, T. Iskov
    Blinkenberg, M.
    Petersen, T.
    Ravnborg, M.
    Chalmer, T.
    Sorensen, P. Soelberg
    Magyari, M.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 905 - 906
  • [27] Final results of the SAME (Swiss Analysis of Multiple Sclerosis) study comparing four disease-modifying treatments for multiple sclerosis
    Gobbi, C.
    Zecca, C.
    Linnebank, M.
    Mueller, S.
    Meier, R.
    Borter, E.
    Traber, M.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S422 - S422
  • [28] Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis
    Hartung, Hans-Peter
    Meuth, Sven G.
    Thompson, Alan J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (10) : 1473 - 1476
  • [29] A PRAGMATIC LITERATURE REVIEW OF NETWORK META-ANALYSES OF DISEASE-MODIFYING DRUGS IN THE TREATMENT OF MULTIPLE SCLEROSIS
    Phillips, A. L.
    Beckerman, R.
    Smith, N. J.
    Locklear, J. C.
    Jiang, Y.
    Solon, C.
    VALUE IN HEALTH, 2015, 18 (03) : A34 - A34
  • [30] The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans
    Ozminkowski, RJ
    Marder, WD
    Hawkins, K
    Wang, SH
    Stallings, SC
    Finkelstein, SN
    Sinskey, AJ
    Wierz, D
    CLINICAL THERAPEUTICS, 2004, 26 (08) : 1341 - 1354
12345